Early trial tests unapproved liver drug in kidney patients
NCT ID NCT07262333
Summary
This early-stage study is checking how a potential new drug for liver scarring is processed by the body and how safe it is for people with reduced kidney function. It will compare 56 participants, including healthy volunteers and people with mild to severe kidney problems, after they take a single dose. The main goal is to understand if the drug behaves differently in people with kidney issues to guide future use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGHubei, Wuhan, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.